# Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma

> **NCT04354324** · NA · UNKNOWN · sponsor: **Zhujiang Hospital** · enrollment: 254 (estimated)

## Conditions studied

- Papillary Thyroid Cancer

## Interventions

- **DRUG:** Radioiodine

## Key facts

- **NCT ID:** NCT04354324
- **Lead sponsor:** Zhujiang Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-20
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 254 (ESTIMATED)
- **Last updated:** 2024-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04354324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04354324, "Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT04354324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*